Bioresorbable Polymers Market Forecast and Outlook By Fact.MR
- In 2025, the bioresorbable polymers market was valued at USD 2.4 billion.
- Based on Fact.MR analysis, demand for bioresorbable polymers is estimated to grow to USD 2.8 billion in 2026 and USD 13.3 billion by 2036.
- FACT.MR projects a CAGR of 16.9% during the forecast period.
| Metric |
Value |
| Estimated Value in 2026 |
USD 2.8 billion |
| Forecast Value in 2036 |
USD 13.3 billion |
| Forecast CAGR (2026 to 2036) |
16.9% |
Summary of Bioresorbable Polymers Market
- Demand Drivers
- Medical device manufacturers are using more bioresorbable polymers in orthopedic implants. Absorbable implants reduce the need for removal surgeries.
- Pharmaceutical companies are increasing research in controlled-release drug delivery systems. Biodegradable polymers help improve drug stability and treatment results.
- Biotechnology research centers are investing more in tissue engineering. Regenerative medicine programs are growing in advanced healthcare markets and support biological repair work.
- Key Segments Analyzed
- By Material Type: Polylactic Acid (PLA) accounts for nearly 35% share in 2026 due to broad medical implant usage.
- By Application: Drug Delivery Systems generate nearly 30% share in 2026 due to rising controlled-release therapies.
- By Manufacturing Process: Injection Molding contributes nearly 40% share in 2026 due to efficient medical device production compatibility.
- By Form: Fibers hold nearly 38% share in 2026 due to rising surgical suture and wound care demand.
- By End-use Industry: Healthcare accounts for nearly 45% share in 2026 due to expanding absorbable implant adoption.
- By Geography: India is projected to expand at 19.1% CAGR through 2036 due to rising domestic medical manufacturing investment.
- Analyst Opinion at Fact.MR
- Shambhu Nath Jha, Principal Consultant at Fact.MR, opines, ‘CXOs will observe faster replacement of permanent implant materials in the healthcare sector. Hospitals are increasingly shifting toward biodegradable medical polymer systems. These materials reduce long-term complications and the need for secondary surgeries.’
- Strategic Implications
- Bioresorbable polymer manufacturers should build closer ties with medical device companies in India and China. Implant production is rising in both countries.
- Pharmaceutical companies should increase research in controlled-release drug formulations. Biodegradable polymers can improve treatment accuracy.
- Medical polymer suppliers should invest in high-purity PLA and PLGA production. This can support stronger use in medical implant.
- The market is projected to create USD 10.5 billion in additional revenue through 2036. Growth is rising due to wider absorbable implant use and higher investment in controlled drug delivery systems. High material development cost limits faster use among smaller medical device manufacturers.
India is projected to expand at 19.1% CAGR through 2036 as domestic medical manufacturing capacity and surgical procedure volumes increase. China is forecast to grow at 18.0% CAGR through 2036 due to rising biodegradable implant production and healthcare investment. United States demand is expected to increase at 17.2% CAGR through 2036 supported by drug delivery research activity and advanced medical device adoption. South Korea is projected to record 16.8% CAGR through 2036 as biotechnology manufacturing and regenerative medicine programs expand. Germany is forecast to expand at 16.1% CAGR through 2036 due to rising orthopedic implant development and medical polymer processing investment. Japan is projected to grow at 15.4% CAGR through 2036 as healthcare companies increase biodegradable polymer use across cardiovascular and tissue engineering applications.
Segmental Analysis
Bioresorbable Polymers Market Analysis by Material Type
Polylactic Acid (PLA) is estimated to hold 35% share in 2026. Medical device manufacturers prefer PLA for its biocompatibility and stable breakdown in implant use. Surgical product developers are using more PLA in orthopedic fixation and absorbable sutures.
- NatureWorks opens Ingeo biopolymer facility in Thailand: NatureWorks has opened its fully integrated Ingeo biopolymer facility in Nakhon Sawan in Thailand. The site combines lactic acid production with lactide and polymer output in one complex to expand global PLA capacity. [1]
- Medical Device Development: Healthcare manufacturers are increasing PLA-based implant development for absorbable orthopedic fixation.
- Implant Material Adoption: Hospital surgical centers are using more biodegradable polymer implants to reduce secondary removal procedures.
Bioresorbable Polymers Market Analysis by Application
Drug Delivery Systems account for 30% share in 2026. Pharmaceutical developers prefer biodegradable polymers for controlled-release drug delivery and fewer post-treatment complications. Advanced therapy research is increasing polymer use in injectable and implantable drug delivery systems.
- Controlled-release Expansion: Pharmaceutical companies are using more biodegradable polymers in long-duration therapeutic delivery products.
- Evonik expands RESOMER® bioresorbable polymer capacity: Evonik has expanded RESOMER® powder biomaterial production capacity at its Darmstadt site in Germany. The company added solvent-free micronization technology to make customized bioresorbable polymer powders with controlled particle size and degradation profiles. [2]
- Biopharma Research Growth: Biotechnology companies are using more biodegradable polymers in targeted therapy development programs.
Bioresorbable Polymers Market Analysis by Manufacturing Process
Injection Molding holds 40% share in 2026. Medical device manufacturers prefer injection molding for scalable production and precise component making. Implant developers are increasing injection molded biodegradable product output for healthcare use.
- Precision Manufacturing Demand: Medical device facilities are using more injection molding in absorbable implant production.
- 3D Printing Expansion: Healthcare research organizations are using more biodegradable polymers for customized implant printing.
- Manufacturing Technology Investment: Medical polymer processors are expanding automated molding systems to improve production consistency and reduce defects.
Bioresorbable Polymers Market Analysis by Form
Fibers account for 38% share in 2026. Surgical manufacturers prefer fiber-based biodegradable polymers because they are widely used in sutures and wound care products. Healthcare facilities are increasing absorbable fiber use in post-surgical treatment.
- Surgical Suture Demand: Hospitals are using more biodegradable fibers in absorbable wound closure procedures.
- Formerra expands Foster Medical Compounds distribution to Europe: Formerra has expanded its agreement with GEON Performance Solutions to become the preferred distributor of Foster® medical compounds in Europe. The partnership improves access to medical-grade engineered polymers used in drug delivery systems and implantable medical devices. [3]
- Wound Care Growth: Healthcare providers are using more biodegradable dressings in advanced wound care.
Bioresorbable Polymers Market Analysis by End-use Industry
Healthcare contributes 45% share in 2026. Hospitals and surgical centers create demand for biodegradable polymers in implants and sutures. Medical treatment expansion is increasing healthcare polymer use globally.
- Implant Surgery Expansion: Healthcare systems are using more biodegradable implants in orthopedic and cardiovascular procedures.
- Biotechnology Research Activity: Research institutes are developing more biodegradable scaffolds for regenerative medicine programs.
- Bioretec receives FDA Breakthrough for RemeOs™ DrillPin: Bioretec has received FDA Breakthrough Device Designation for its RemeOs™ DrillPin. The product is a magnesium alloy based biodegradable orthopedic implant. [4]
Drivers, Restraints, and Opportunities
Fact.MR analysis shows the bioresorbable polymers market as a fast-growing healthcare materials sector. Demand is rising due to higher use of absorbable implants and new pharmaceutical applications. Medical manufacturers are using more biodegradable polymers to support patient recovery and reduce long-term surgical complications.
Permanent implant materials are facing replacement pressure in orthopedic and cardiovascular applications. Drug delivery developers prefer biodegradable systems because they support controlled therapeutic release. High material development cost partly limits adoption among smaller healthcare manufacturing facilities.
- FDA Approval Activity: Rising FDA approvals for absorbable implants and controlled-release therapies are increasing medical polymer demand in the United States and Europe.
- Asian Manufacturing Expansion: Medical polymer processing capacity is growing in China and India as domestic healthcare manufacturing investment increases.
- Bioretec’s disappearing devices make lasting impact: Bioretec develops fully absorbable orthopedic implants that dissolve inside the body after completing their function. Its Activa and RemeOs product lines use biodegradable materials such as PLGA and magnesium alloys to support bone healing without leaving permanent implants. [5]
Regional Analysis
The bioresorbable polymers market is assessed across North America, Europe, Asia Pacific, Latin America, and Middle East and Africa covering medical polymer production, healthcare investment, pharmaceutical innovation, and implant manufacturing activity. The full report offers market attractiveness analysis by region and country.
.webp "Top Country Growth Comparison Bioresorbable Polymers Market Cagr (2026 2036)")
| Country |
CAGR (2026 to 2036) |
| India |
19.1% |
| China |
18.0% |
| United States |
17.2% |
| South Korea |
16.8% |
| Germany |
16.1% |
Asia Pacific Bioresorbable Polymers Market Analysis
Asia Pacific is the fastest-growing bioresorbable polymers market. Growth comes from expanding healthcare manufacturing and higher investment in regenerative medicine. Corbion N.V. and Evonik Industries AG hold key positions through medical polymer supply and healthcare partnerships in the region.
- India: Demand for bioresorbable polymers in India is projected to rise at 19.1% CAGR through 2036. Medical device manufacturing investment increased in Gujarat and Maharashtra during 2025. This supports biodegradable implant production. Government incentives are increasing local biodegradable polymer processing across surgical device facilities.
- China: China is projected to expand at 18.0% CAGR through 2036 as absorbable implant production and biotechnology investment increase. Medical polymer processing facilities in Shanghai and Guangdong expanded biodegradable material manufacturing during 2024. Hospital modernization is increasing biodegradable implant use in orthopedic and cardiovascular procedures.
- South Korea: South Korea records 16.8% CAGR through 2036 as regenerative medicine and biotechnology manufacturing expand. Research institutes increased biodegradable scaffold development programs in Seoul and Incheon during 2025. Medical polymer manufacturers are improving supply for tissue engineering applications.
- Japan: Japan is expected to expand at 15.4% CAGR through 2036 as cardiovascular device development and tissue engineering investment rise. Healthcare manufacturers increased biodegradable polymer research during 2024 to support regenerative medicine applications. Aging population trends are increasing demand for absorbable medical implants in advanced surgical procedures.
FACT.MR's Asia Pacific analysis covers China, India, Japan, South Korea, ASEAN, and Australia and New Zealand. Readers can find healthcare manufacturing trends and biodegradable polymer demand benchmarks across medical applications.
North America Bioresorbable Polymers Market Analysis
North America is a high-value bioresorbable polymers market. Advanced healthcare infrastructure and pharmaceutical research investment support demand. Foster Corporation and Poly-Med Inc. hold key regional positions through medical polymer development and healthcare partnerships.
- United States: Demand for bioresorbable polymers in the United States is projected to rise at 17.2% CAGR through 2036. FDA approvals for absorbable implants and drug delivery systems increased during 2024. This supports biodegradable polymer demand. Pharmaceutical research organizations are increasing controlled-release therapy development across biotechnology and advanced healthcare facilities.
FACT.MR's North America analysis covers the United States, Canada, and Mexico. Readers can find pharmaceutical innovation trends and medical polymer investment benchmarks across healthcare manufacturing industries.
Europe Bioresorbable Polymers Market Analysis
Europe is a regulation-focused bioresorbable polymers market. Advanced medical manufacturing and healthcare innovation programs support demand. Evonik Industries AG and KLS Martin Group hold key positions through biodegradable implant development and healthcare material research.
- Germany: Germany is projected to record 16.1% CAGR through 2036 due to rising orthopedic implant production and healthcare manufacturing investment. Medical device companies in Bavaria expanded biodegradable polymer processing during 2025. This supports absorbable implant output. Hospital surgical centers are using more biodegradable fixation systems in trauma and orthopedic procedures.
FACT.MR's Europe analysis covers Germany, United Kingdom, France, Italy, Spain, BENELUX, Nordic Countries, and Rest of Europe. Readers can find healthcare manufacturing benchmarks and biodegradable polymer demand trends across medical applications.
Competitive Aligners for Market Players
p>Competition in the bioresorbable polymers market centers on medical-grade purity and healthcare regulatory capability. Large polymer manufacturers are increasing investment in absorbable implant materials and pharmaceutical delivery technologies. Healthcare manufacturers prefer suppliers with stronger quality certification and long-term technical support capability.
Evonik Industries AG and Corbion N.V. maintain competitive positioning through advanced biodegradable polymer production and healthcare material development. Foster Corporation and Poly-Med Inc. strengthen commercial positioning through custom medical polymer formulation capability. Medical device manufacturers are increasing preference for suppliers offering stable regulatory documentation and consistent polymer performance.
Healthcare companies are increasing long-term supply agreements due to rising absorbable implant demand. Pharmaceutical developers prefer suppliers with controlled production quality and faster formulation support capability. Biodegradable polymer producers with stronger manufacturing scalability are improving pricing discipline across advanced healthcare applications.
Key Players
- Corbion N.V.
- Evonik Industries AG
- Poly-Med, Inc.
- KLS Martin Group
- Foster Corporation
- Ashland Global Holdings Inc.
Bibliography
- Evonik Industries AG. (2024, April). Evonik expands capacity for customized RESOMER® powder biomaterials.
- NatureWorks LLC. (2026, April 29). NatureWorks announces grand opening of fully integrated Ingeo biopolymer manufacturing facility in Thailand.
- Formerra. (2026). Formerra expands Foster Medical Compounds distribution to Europe.
- Bioretec Ltd. (2025). Inside information: Bioretec has been granted FDA Breakthrough Device Designation status for its RemeOs™ DrillPin.
- Bioretec Ltd. (2025). Bioretec’s disappearing devices make lasting impact.
This Report Addresses
- Strategic intelligence covering bioresorbable polymer demand across healthcare and pharmaceutical manufacturing applications.
- Market forecast from USD 2.8 billion in 2026 to USD 13.3 billion by 2036 at 16.9% CAGR.
- Growth opportunity analysis across India healthcare manufacturing and China biodegradable implant production expansion.
- Segment analysis across material type, application, manufacturing process, form, and end-use industry with 2026 benchmarks.
- Regional outlook covering Asia Pacific healthcare manufacturing and North America pharmaceutical innovation trends.
- Competitive analysis of Corbion N.V., Evonik Industries AG, Poly-Med Inc., and Foster Corporation.
- Regulatory analysis covering FDA approvals and EU MDR compliance across biodegradable medical materials.
Bioresorbable Polymers Market Definition
The bioresorbable polymers market covers biodegradable polymer materials used across medical implants, drug delivery systems, wound care products, and tissue engineering applications. These polymers gradually break down inside the body after completing their medical function. Healthcare manufacturers use bioresorbable polymers to reduce long-term implant removal procedures and improve patient recovery outcomes.
Bioresorbable Polymers Market Inclusions
The study covers global and regional forecasts from 2026 to 2036 across material type, application, manufacturing process, form, and end-use industry. It includes synthetic and natural bioresorbable polymers supplied for biotechnology, healthcare, pharmaceutical, and medical device manufacturing applications.
Bioresorbable Polymers Market Exclusions
The study excludes non-biodegradable engineering plastics and permanent implant polymers unless integrated into hybrid absorbable systems. It omits consumer healthcare products and cosmetic biodegradable materials outside regulated medical and pharmaceutical applications.
Bioresorbable Polymers Market Research Methodology
- Primary Research
- Primary research includes interviews with biomaterial scientists, medical device engineers, and pharmaceutical formulation specialists. Hospital teams and biotechnology manufacturing executives across the United States, Germany, and Japan were included.
- Desk Research
- Desk research uses public disclosures from Corbion N.V., Evonik Industries AG, and Foster Corporation. FDA approvals and EU MDR regulatory updates from 2024 and 2025 were reviewed.
- Market-Sizing and Forecasting
- Market sizing applies a hybrid top-down and bottom-up model. Medical implant shipment volumes, pharmaceutical drug delivery pipeline activity, and biodegradable polymer production capacity form the core forecast inputs.
- Data Validation and Update Cycle
- Data validation uses medical polymer revenue disclosures and healthcare device shipment benchmarks from 2024 and 2025 company filings. Findings are cross-checked with medical device engineers and biomaterial specialists.
